...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the advanced practitioner in oncology >Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia
【24h】

Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia

机译：依从性对伊布洛尼布的影响对现实世界慢性淋巴细胞白血病患者临床结果的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a first-line treatment option, and recent data suggest that strict adherence is directly related to clinical outcomes. Objectives: The primary objective of this study was to quantify ibrutinib adherence rates in real-world patients with CLL on ibrutinib; secondary outcomes included progression-free survival and overall survival. Methods: This retrospective study included subjects who were treated at a large academic medical center over approximately 5 years. Subjects were at least 18 years, diagnosed with CLL or small lymphocytic lymphoma, and treated with ibrutinib monotherapy for at least 6 months. Adherence was quantified using the medication possession ratio (MPR), which is the ratio of the sum of days' supply of medication in a period over the number of days in that period, and was based on fill history from the medical center's specialty pharmacy. Results: For the 32 subjects in this study, the mean ibrutinib adherence rate was 91.7% (range, 84.4%-100%). Only 3 subjects had disease progression, and 1 death was recorded while on therapy (all with MPR < 95%); therefore, analyses of clinical outcomes were unable to be assessed due to a low number of events. There were no statistically significant differences in rates of adherence based on baseline characteristics and adverse drug events. Conclusion: In patients with CLL treated with ibrutinib, mean adherence was 91.7%, which is lower than rates seen in clinical trials.
机译：背景：慢性淋巴细胞白血病（CLL）是一种B细胞肿瘤，伴有小淋巴细胞克隆性扩增。伊布替尼是布鲁顿酪氨酸激酶（BTK）的不可逆抑制剂，是一线治疗选择，最近的数据表明严格依从与临床结果直接相关。目的：本研究的主要目的是量化使用伊布替尼的CLL患者的依从率；次要结果包括无进展生存率和总生存率。方法：这项回顾性研究包括在大型学术医疗中心接受治疗超过5年的受试者。受试者至少18岁，被诊断为CLL或小淋巴细胞淋巴瘤，并接受伊布替尼单药治疗至少6个月。使用药物占有率（MPR）对依从性进行量化，MPR是一段时间内药物供应天数与该期间天数之和的比率，并基于医疗中心专业药房的填写历史。结果：在本研究的32名受试者中，伊布替尼的平均依从率为91.7%（范围为84.4%-100%）。只有3名受试者出现疾病进展，1名患者在接受治疗时死亡（所有患者的MPR均<95%）；因此，由于事件数量较少，无法评估临床结果分析。根据基线特征和药物不良事件，依从率没有统计学上的显著差异。结论：伊布替尼治疗的CLL患者的平均依从性为91.7%，低于临床试验的依从率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号